Vorinostat is marketed under the name '''Zolinza''' ({{IPAc-en|z|oʊ|ˈ|l|ɪ|n|z|ə}} {{respell|zoh|LIN|zə}}) by [[Merck & Co.|Merck]] for the treatment of cutaneous manifestations in patients with [[cutaneous T cell lymphoma]] (CTCL) when the disease persists, gets worse, or comes back during or after two systemic therapies.<ref name="Zolinza PI" /><ref>{{cite press release | title = ZOLINZA, Merck's Investigational Medicine for Advanced Cutaneous T-Cell Lymphoma (CTCL), To Receive Priority Review from U.S. Food and Drug Administration | publisher = Merck & Co. | date = June 7, 2006 | url = http://www.merck.com/newsroom/press_releases/research_and_development/2006_0607.html | accessdate = 2006-10-06 }}</ref> The compound was developed by Columbia University chemist [[Ronald Breslow]] and Memorial Sloan-Kettering researcher Paul Marks.<ref>{{cite journal |last1=Lee |first1=J.-H. |last2=Mahendran |first2=A. |last3=Yao |first3=Y. |last4=Ngo |first4=L. |last5=Venta-Perez |first5=G. |last6=Choy |first6=M. L. |last7=Kim |first7=N. |last8=Ham |first8=W.-S. |last9=Breslow |first9=R. |last10=Marks |first10=P. A. |title=Development of a histone deacetylase 6 inhibitor and its biological effects |journal=Proceedings of the National Academy of Sciences |volume=110 |issue=39 |pages=15704–9 |year=2013 |pmid=24023063 |pmc=3785767 |doi=10.1073/pnas.1313893110 |bibcode=2013PNAS..11015704L }}</ref><ref>{{cite journal |last1=Marks |first1=Paul A |last2=Breslow |first2=Ronald |title=Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug |journal=Nature Biotechnology |volume=25 |issue=1 |pages=84–90 |year=2007 |pmid=17211407 |doi=10.1038/nbt1272 }}</ref>

 
Vorinostat was the first [[histone deacetylase inhibitor]]<ref>[http://www.hdacis.com/zolinza.html HDAC Inhibitors Base (vorinostat)]</ref> approved by the U.S. [[Food and Drug Administration]] (FDA) for the treatment of CTCL on October 6, 2006.<ref name = MSR>{{cite web|title=Zolinza (vorinostat) dosing, indications, interactions, adverse effects, and more|work=Medscape Reference|publisher=WebMD|accessdate=16 February 2014|url=http://reference.medscape.com/drug/zolinza-vorinostat-342102}}</ref> It also failed to demonstrate efficacy in treating [[acute myeloid leukemia]] in a phase II study.<ref>{{cite journal |last1=Schaefer |first1=E. W. |last2=Loaiza-Bonilla |first2=A. |last3=Juckett |first3=M. |last4=DiPersio |first4=J. F. |last5=Roy |first5=V. |last6=Slack |first6=J. |last7=Wu |first7=W. |last8=Laumann |first8=K. |last9=Espinoza-Delgado |first9=I. |last10=Gore |first10=S. D. |title=A phase 2 study of vorinostat in acute myeloid leukemia |journal=Haematologica |volume=94 |issue=10 |pages=1375–82 |year=2009 |pmid=19794082 |pmc=2754953 |doi=10.3324/haematol.2009.009217 }}</ref>

 
Vorinostat is an interesting target for scientists interested in eradicating [[HIV]] from infected persons.<ref>{{ClinicalTrialsGov|NCT01319383|The Effect of Vorinostat on HIV RNA Expression in the Resting CD4+ T Cells of HIV+ Pts on Stable ART}}</ref> Vorinostat was recently shown to have both ''in vitro'' and ''in vivo'' effects against latently HIV infected [[T cell]]s.<ref name="pmid19239360">{{cite journal |last1=Archin |first1=Nancie M. |last2=Espeseth |first2=Amy |last3=Parker |first3=Daniel |last4=Cheema |first4=Manzoor |last5=Hazuda |first5=Daria |last6=Margolis |first6=David M. |title=Expression of Latent HIV Induced by the Potent HDAC Inhibitor Suberoylanilide Hydroxamic Acid |journal=AIDS Research and Human Retroviruses |volume=25 |issue=2 |pages=207–12 |year=2009 |pmid=19239360 |pmc=2853863 |doi=10.1089/aid.2008.0191 }}</ref><ref name="pmid19136668">{{cite journal |last1=Contreras |first1=X. |last2=Schweneker |first2=M. |last3=Chen |first3=C.-S. |last4=McCune |first4=J. M. |last5=Deeks |first5=S. G. |last6=Martin |first6=J. |last7=Peterlin |first7=B. M. |title=Suberoylanilide Hydroxamic Acid Reactivates HIV from Latently Infected Cells |journal=Journal of Biological Chemistry |volume=284 |issue=11 |pages=6782–9 |year=2009 |pmid=19136668 |pmc=2652322 |doi=10.1074/jbc.M807898200 }}</ref>
